CYP2D6 and attention deficit-hyperactivity disorder: The first PGx-based dosing guidelines relevant to psychiatry were published in 2008 by the DPWG and included dosing recommendations for antidepressants (i.e. clomipramine, imipramine, nortriptyline, paroxetine, and venlafaxine), antipsychotics (i.e. haloperidol, risperidone, and zuclopenthixol), and one medication (i.e. atomoxetine) for attention-deficit hyperactivity disorder (ADHD) based on CYP2D6 genotype (Swen et al., 2008).